March is World Myeloma Action Month. It is a chronic malignant disease of the blood system. Unlike many other types of cancer, it does not manifest itself as a single tumor, but as an accumulation of abnormal plasma cells in the bone marrow and the presence of abnormal protein in the blood.
This is a fairly rare cancer, diagnosed most often in elderly people, and the main causes of its occurrence have not yet been identified. Provoking factors may include genetic predisposition, radiation, exposure to toxic chemicals and others. Throughout March, people with myeloma, as well as their families, friends and caregivers, are raising awareness of the disease and advocating for action initiatives.
Myeloma disease is diagnosed and treated by a hematologic oncologist, a physician who specializes in malignant neoplasms of the blood. Laboratory and instrumental diagnostic methods, examination and interview of the patient are used to make a diagnosis.
Approaches to the treatment of multiple myeloma differ depending on the patient’s condition, stage of the disease, etc. Currently, multiple myeloma is completely incurable, but new drugs and modern innovative therapy allow patients to go into long-term remission – this is a huge scientific breakthrough. After basic therapy, periodic check-ups (every 3-6 months) and maintenance therapy are required.
To find out more about GCT’s experience in Oncology Clinical Trials you can contact us at bd@gctrials.com.